Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jan-Mar;8(1):13-7.
doi: 10.4103/0974-1208.153120.

Revisiting ovarian hyper stimulation syndrome: Towards OHSS free clinic

Manish Banker  1 , Juan A Garcia-Velasco  2
Affiliations
Review

Revisiting ovarian hyper stimulation syndrome: Towards OHSS free clinic

Manish Banker et al. J Hum Reprod Sci. 2015 Jan-Mar.

Abstract

A rapid development and application of assisted reproductive technologies (ARTs) and ovulation-induction drugs may lead to ovarian hyper stimulation syndrome (OHSS). Young age, low body mass index (BMI), polycystic ovarian syndrome (PCOS), previous OHSS, high follicle count, and elevated serum estradiol (E2) are the certain factors that predispose women to OHSS. Many strategies have been used to reduce or avoid OHSS. Use of human chorionic gonadotropin (hCG) increases ovarian vascular permeability and is responsible for activating the vascular endothelial growth factors (VEGF) pathway and thus the entire cascade, leading to symptomatic OHSS. Gonadotropin-releasing hormone (GnRH) agonists are used as a replacement for hCG for final oocyte maturation in antagonist cycles. Reducing or eliminating the use of hCG and use of GnRH agonist triggered GnRH antagonist cycles and cryopreservation of oocytes or embryos is the most promising approach in making OHSS free clinic a reality.

Keywords: Agonist; GnRH; and hCG; antagonist; assisted reproductive technology.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): A review. Hum Reprod Update. 2002;8:559–77. - PubMed
    1. Lyons CA, Wheeler CA, Frishman GN, Hackett RJ, Seifer DB, Haning RV., Jr Early and late presentation of the ovarian hyperstimulation syndrome: Two distinct entities with different risk factors. Hum Reprod. 1994;9:792–9. - PubMed
    1. Bulun SE, EY . The physiology and pathology of the female reproductive axis. In: Kronenberg H.K., editor. Williams textbook of endocrinology. 11th ed. Philadelphia: Saunders; 2008.
    1. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: Prevention and treatment. Fertil Steril. 1992;58:249–61. - PubMed
    1. Delvigne A, Demoulin A, Smitz J, Donnez J, Koninckx P, Dhont M, et al. The ovarian hyperstimulation syndrome in in-vitro fertilization: A Belgian multicentric study. I. Clinical and biological features. Hum Reprod. 1993;8:1353–60. - PubMed

LinkOut - more resources